

Navigating Biopharma Innovation Across the Pacific

Join us for an engaging event focused on bridging the gap between U.S. investment and the Japanese biotech industry, where we will discuss key challenges and explore potential solutions. Attendees will connect with Japanese startups, government officials, and academics, gaining insights into the biotech startup lifecycle through firsthand experiences from founders and investors. Together, we aim to ignite interest in biotechnology entrepreneurship while identifying mutual investment opportunities and addressing structural obstacles in cross-border collaboration.

WHEN

Navigating Biopharma Innovation Across the Pacific

Monday, November 11, 2024

12:00–5:00 PM

WHERE

Akasaka Intercity Conference

Room: The Amphitheater

Akasaka Intercity Conference Center

3F and 4F, Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052

—AGENDA —

Tokyo, Monday, November 11, 2024

*Invitation Only

12:00 P.M. – 12:30 P.M.

REGISTRATION

12:30 P.M. – 12:45 P.M.

OPENING OF THE SYMPOSIUM, WELCOME REMARKS

SESSION 1: INGREDIENTS FOR A SUCCESSFUL TRANSPACIFIC BIOTECH COMPANY

Moderator: Seth Flaum | Partner, Wilson Sonsini Goodrich & Rosati



Seth Flaum is a partner in the New York office of Wilson Sonsini Goodrich & Rosati and a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters.

Prior to joining the firm, Seth was executive associate general counsel for Daiichi Sankyo, Inc., a global pharmaceutical company based in Japan, where he advised on an array of strategic transactions and managed a team of lawyers and business professionals responsible for implementing the company's global business development transactions. In this role, Seth counseled on strategic transactions, collaborations, licensing agreements, research and development agreements, and other commercialization related transactions. He also has experience with public and private M&A transactions, and has advised on antitrust issues and filings, FINRA inquiries, SEC filings, and corporate governance matters.

Before joining Daiichi Sankyo, Seth was a senior associate at Ullman, Shapiro & Ullman, LLP in New York.

Keita Mori | SanBio



Mr. Mori has been Chief Executive Officer and has served as a member of the Board since SanBio's inception in 2001. Prior to founding SanBio, Mr. Mori was Head of New Product Development from 2000 to 2001 at Xuma, an informatics startup in San Francisco. From 1993 to 1999, Mr. Mori held positions of increasing responsibility in R&D and Manufacturing at Kirin Holdings, Ltd. in Japan. Mr. Mori holds an MBA degree from the University of California, Berkeley and a master's degree in Biochemistry from the University of Tokyo.

Haru Morita | President and CEO, Modalis Therapeutics



Haru is a dynamic entrepreneur and investor whose leadership and strategic vision have led Modalis (TSE 4883) to success since its inception in 2016. He has 30 years of experience in the biotechnology industry, including as CEO of REGiMMUNE, which he founded to harness the power of regulatory T cells to manage difficult-to-treat immune

12:45 P.M. – 1:45 P.M.

disorders such as GVHD. Before that, he held a leading role at Y's Therapeutics, which was developing novel antibody therapeutics. In addition, at Kirin (merged with Kyowa Kirin), he played an important role as a researcher, and at Booz Allen Hamilton (merged with PwC's Strategy &), he was involved in numerous projects in various industry sectors.

Ryosuke Gonotsubo | Shinobi Therapeutics

SESSION 2: GETTING THE INSIDE SCOOP ON VC'S

Azusa Shiohara | Principal Investment Professional, The University of Tokyo Edge Capital

Azusa Shiohara is an investment professional in the field of biotech investments. She joined UTEC in September 2021, where she focuses on seed and early-stage investments. Prior to her role at UTEC, Azusa worked as a manager on the biotech and healthcare team at Arthur D Little, a global management consulting firm. There, she specialized in supporting clients in the life science sector with new business development and R&D strategies. Azusa holds an MBA from the London Business School and an MSc in Pharmaceutical Sciences from the University of Tokyo.

Kathryn Zavala, PhD | Chief Operating Officer, MedTech Innovator & MedtechVISION 2024 Planning Committee



Kathryn Zavala, PhD, is Chief Operating Officer of MedTech Innovator, the largest accelerator of medical devices in the world. In 2016, she helped spin the nonprofit entity out of the venture capital firm where it was founded and has been instrumental in expanding the organization. To date, MedTech Innovator has supported 612 alumni that have gone on to raise over \$7.8 billion in follow-on equity funding and achieved 45 exits. In 2021, Kathryn launched and now serves as Managing Director of BioTools Innovator, a new program powered by MedTech Innovator to support life science tools.

Kathryn previously held positions at the UCLA Technology Development Group, where she assisted with the commercialization of university technologies, and at Campbell Alliance (now Syneos Health), where she developed launch strategies for biopharma clients. Kathryn received a Bachelor's degree in Molecular and Cell Biology and Rhetoric from UC Berkeley and a PhD in Molecular, Cell, and Developmental Biology from UCLA.

Takeshi Takahashi, M.B.A. | Managing Director, Catalys Pacific, LLC



Takeshi Takahashi is a Managing Director with Catalys Pacific. He holds extensive experience in M&As, IPOs, and financing in the healthcare sector. Prior to Catalys Pacific, he worked for the investment banking division of Morgan Stanley for 12 years and played a significant role in over 30 distinguished transactions including, but not

2:00 P.M. – 3:00 P.M.

limited to, Japanese companies' acquisitions of U.S. listed companies with an enterprise value of over US\$10.0 billion, acquisitions of global healthcare companies with an enterprise value of over US\$5.0 billion, and a number of alternative financing transactions. Prior to working for Morgan Stanley, Takeshi was an analyst and a portfolio manager for global and Japan fixed income and managed a \$3.0+ billion portfolio in Japan and the U.S. at Merrill Lynch's asset management division.

Takeshi graduated from Waseda University with a degree in Political Science and Economics, and holds an M.B.A. from Kellogg School of Management at Northwestern University. Proficiently bilingual and bicultural.

SESSION 3: INDUSTRY/POLICY EXPERTISE

Moderator: Dr. Fumiaki Ikeno | MD, Stanford University School of Medicine



After graduating from Jichi Medical University, he began practicing general medicine in the rural areas of Japan. Fumiaki joined the Department of Cardiovascular Medicine at Stanford University in 2001, and was closely involved with the R&D, animal studies, and clinical studies of many medical device startups. He is also actively involved in projects with the US and Japanese regulatory agencies working to create an effective cross-border medical device eco-system. Fumiaki has also been an advisory faculty for the Stanford Biodesign Program since 2014. He is deeply involved with the development of the Japan Biodesign Program and is working diligently to establish a Silicon Valley-like medical device eco-system in Japan.

Keiko Oishi | President and COO, CMIC HOLDINGS Co. Ltd.



Ms. Oishi is the President and COO of CMIC HOLDINGS Co. Ltd., responsible for group-wide business execution.

Ms. Oishi received her Master of Science degree from the University of Tokyo. She started her career at Nikkei McGraw-Hill, Inc. in Japan (now renamed Nikkei Business Publications), as a staff writer for Nikkei Biotech, the first Japanese newsletter specializing in biotechnology. She accumulated her biotechnology industry career through working in Genzyme Japan, Ltd., and Genentech, Ltd., a Japanese Branch of Genentech, Inc. in the U.S.

Ms. Oishi joined CMIC in 1996, as Manager of the Strategy Development Department. Over the past 20 years, she has been responsible for International Business and Corporate Development, covering Japan, Korea, China, Singapore, Taiwan and other regions in Asia Pacific, as well as for International Business Development which function could bring in foreign pharma and biotech companies that are interested in drug development in Japan and Asia, to start their regulatory and clinical activities in the region. With her broad international experience and strong leadership, she continuously leads the company to further globalization.

Tomoyoshi Koyanagi, Ph.D. | Program-Specific Professor, Director of Business Development Office, Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital

3:15 P.M. – 4:15 P.M.



Prof. Koyanagi is a highly accomplished business development professional with deep expertise in the medical startup ecosystem. At Kyoto University, he led collaborations between academia and major pharmaceutical, diagnostics, and telecommunications companies, driving next-generation medical innovations. Currently, he oversees partnerships between startups and the university hospital, acting as a key connector among global life sciences stakeholders. Since 2016, he has been the lead advisor for HVC KYOTO and co-founded the Research Studio program during his tenure as a professor at the University of Tsukuba's Medical School. Prof. Koyanagi also brings extensive marketing and project management experience from his work with multinational corporations and startups. He earned his Ph.D. from Osaka University and completed post-doctoral training at Stanford University.

Tadayuki Mizutani | Director of Policy Planning Division for Pharmaceutical Industry Promotion and Medical Information Management, Ministry of Health, Labour and Welfare of Japan

SESSION 4: STAGES OF A STARTUP & THE ENTREPRENEURIAL MINDSET

Rieko Yajima | Director of Drug Discovery Innovation, Stanford SPARK

4:30 P.M. – 5:00 P.M.

Rieko Yajima is the Director of Drug Discovery Innovation at Stanford SPARK. At SPARK, she works with researchers and a community of volunteer industry advisors to de-risk the science in drug discovery and diagnostic projects, and to identify the quickest path to the clinic. She has a Ph.D. in chemical biology and served as a science policy fellow at the U.S. National Academy of Sciences. Her previous roles include being an Associate Program Director at the American Association for the Advancement of Science (AAAS) in Washington, DC, where she advised the scientific community on interdisciplinary research collaboration, implementation, and evaluation, and being a Research Scholar at the Center for Design Research at Stanford University.

5:00 P.M. – 6:30 P.M.

RECEPTION